Bavarian Nordic CEO Paul Chaplin to step down after 27 years

try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices jump 2% amid widening US-Israel conflict with Iran Asia stocks slide as US-Iran strikes batter risk appetite Oil prices surge after US-Israel strikes on Iran, trim early gains Middle East tensions rise as Iran promises retaliation (South Africa Philippines Nigeria) Bavarian Nordic CEO Paul Chaplin to step down after 27 years By Maria Ponnezhath Author Maria Ponnezhath Stock Markets Published 03/02/2026, 02:07 AM Bavarian Nordic CEO Paul Chaplin to step down after 27 years 0 BAVA 0.41% Investing.com -- Bavarian Nordic A/S (OMX:BAVA) said on Monday that CEO Paul Chaplin will step down from his position for personal reasons. Chaplin will remain in his role through the end of 2026 or until a successor is identified, and the Board of Directors has begun the search for a new CEO. Unlock premium chipmaker and AI insights with InvestingPro Chaplin joined Bavarian Nordic in 1999 and was appointed CEO in 2014. During his tenure, he led the development of the company’s smallpox and mpox vaccine. Under his leadership, Bavarian Nordic transformed from a small research-based company with a single government customer into a large vaccine manufacturer with commercial operations in key markets. "I am leaving Bavarian Nordic with great pride. I have truly enjoyed the experiences and professional challenges over nearly three decades and have had the privilege of leading many talented colleagues towards a shared mission of improving and saving lives. We have achieved a lot and created a strong foundation for the future of the company," Chaplin said. "My family wants to relocate back to Australia, but I remain fully committed to the company for the remainder of the year to allow for a stable transition to its next CEO,"